Skip to main content

Novartis works with Microsoft on artificial intelligence

| News

Novartis works with Microsoft on artificial intelligence

02.10.2019

Novartis has selected Microsoft as its new strategic artificial intelligence (AI) and data science partner. With the collaboration, the Basel pharmaceutical giant aims to bolster its AI capacities and promote the development of transformative medicines.

Novartis Campus. (Img: Novartis)

Novartis has founded the Novartis AI Innovation Lab, announced a statement. In a strategic partnership, the Basel pharmaceutical company will work with Microsoft on research and development with two core objectives. Firstly, it will empower every Novartis employee to apply and use AI applications. Secondly, it will use AI to tackle existing challenges in life sciences.

To achieve these aims, Novartis and Microsoft will develop AI platforms to support future programs, while investing in projects, experts, technologies and tools. Novartis wants to continue evolving into a focused medicines company powered by advanced therapy platforms and data science, according to CEO Vas Narasimhan in the statement. “Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world,” he said.

Satya Nadella, CEO of Microsoft, explained that the strategic alliance would address some of the biggest challenges facing the life sciences industry today and could help discover new medicines and reduce patient costs.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.